Tesamorelina
Stabilized GHRH analogue
GHRH analogue approved to reduce visceral fat in HIV lipodystrophy.
Back to technical sheets- Class
- Stabilized GHRH analogue
- Also known as
- Approved as tesamorelin (e.g. Egrifta®) for a specific indication
Mechanism of action
Stabilized GHRH analogue that stimulates endogenous GH secretion, reducing abdominal visceral fat.
Evidence
Clinical evidence: FDA-approved to reduce excess abdominal fat in HIV-associated lipodystrophy, with controlled trials.
Studied uses
- HIV-associated lipodystrophy (visceral fat reduction)
Safety considerations
- Raises IGF-1: oncologic precautions and monitoring
- Do not use in pregnancy or with active malignancy
- Injection-site reactions
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Purity
- ≥ 98 % (HPLC)
- Net content
- 79 %
- Batch
- TES-2601
- Presentation
- Polvo liofilizado en vial sellado
Net content is the fraction of the vial’s weight that is actually peptide, after discounting water, salts and excipients. It is the figure to calculate with, not the label weight.
Sample prices and batch data while the real ones are loaded.
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.